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Malignant gliomas have a poor prognosis despite advances in diagnosis and therapy. Although postoperative temozolomide and
radiotherapy improve overall survival in glioblastoma patients, most patients experience a recurrence. The prognosis of recurrent
malignant gliomas is dismal, and more eﬀective therapeutic strategies are clearly needed. Antiangiogenesis is currently considered
an attractive targeting therapy for malignant gliomas due to its important role in tumor growth. Clinical trials using bevacizumab
have been performed for recurrent glioblastoma, and these studies have shown promising response rates along with progression-
freesurvival.Basedontheencouragingresults,bevacizumabwasapprovedbytheFDAforthetreatmentofrecurrentglioblastoma.
In addition, bevacizumab has shown to be eﬀective for recurrent anaplastic gliomas. Large phase III studies are currently ongoing
to demonstrate the eﬃcacy and safety of the addition of bevacizumab to temozolomide and radiotherapy for newly diagnosed
glioblastoma. In contrast, several other antiangiogenic drugs have also been used in clinical trials. However, previous studies
have not shown whether antiangiogenesis improves the overall survival of malignant gliomas. Speciﬁc severe side eﬀects, diﬃcult
assessmentofresponse,andlackofrationalpredictivemarkersarechallengingproblems.Furtherstudiesarewarrantedtoestablish
the optimized antiangiogenesis therapy for malignant gliomas.
1.Introduction
Malignant gliomas such as glioblastoma and anaplastic
gliomas are the most common primary brain tumors in
adults [1]. Temozolomide and radiotherapy have been
demonstrated to improve overall survival in glioblastoma
patients [2–4]. Despite advances in diagnosis and therapy,
prognosis remains poor with a median overall survival of
12 to 15 months in glioblastoma due to the resistance
to radiotherapy and chemotherapy. Although anaplastic
gliomas tend to respond well to these treatments, the median
survival time is 2 to 3 years [5, 6]. The prognosis of
recurrent malignant gliomas is dismal with the median
overall survival and progression-free survival (PFS) of 7.5
months and 2.5 months, respectively [7]. More eﬀective
therapeutic strategies are needed for these patients.
Malignant gliomas are characterized by vascular prolifer-
ation or angiogenesis [8, 9]. Vascular endothelial growth fac-
tor (VEGF) is highly expressed in glioblastoma and has been
shown to regulate tumor angiogenesis [10]. Bevacizumab
was developed as a humanized monoclonal antibody against
VEGF. Clinical trials of recurrent glioblastoma showed
beneﬁts of bevacizumab in response rate and PFS [11–13].
Based on these favorable results, bevacizumab was approved
by the US Food and Drug Administration (FDA) for
recurrent glioblastoma. For newly diagnosed glioblastoma,
phase II trials showed that the addition of bevacizumab
to temozolomide and radiotherapy improves PFS [14, 15].
Other antiangiogenic drugs have also been investigated and
usedinseveralclinicalstudies[16].Inthispaper,wefocuson
biological and clinical ﬁndings of antiangiogenesis therapy
for malignant gliomas.
2.Biological Aspectsof Antiangiogenic
Therapy for Glioblastoma
Advances in molecular biology have provided pathogenesis
of malignant gliomas. Several clinical and preclinical studies2 Journal of Oncology
proposed thattumor-related blood vessel, called“angiogene-
sis”, is required for solid tumor growth, including malignant
gliomas [10, 16]. Endothelial proliferation is a marker of
histological grading systems for malignant gliomas because
of an association between a degree of microvascularity and
biologic aggressiveness [17]. Glioblastoma is particularly
characterized by vascular proliferation and the extent of
necrosis.Theseﬁndingsindicatethattumorantiangiogenesis
is a promising candidate to inhibit the growth of malignant
gliomas. VEGF, a critical mediator of angiogenesis, has
emergedasanoveltargetofantiangiogenictherapy.Glioblas-
toma cells have been shown to secrete VEGF, resulting in
the endothelial proliferation and tumor survival in vivo [18].
VEGF is expressed in malignant gliomas and is associated
with tumor grade and vascularity [19, 20]. Therefore, it is
postulated that antiangiogenesis suppresses blood ﬂow and
inhibits the tumor growth. Monoclonal antibodies against
VEGF were shown to inhibit the growth of glioma cells in
vivo [21]. A VEGF inhibitor directly aﬀects glioma stem
cells that are more resistant to chemotherapy and radio-
therapy [22]. Furthermore, antiangiogenesis can normalize
tumor vasculature and decrease interstitial ﬂuid pressure,
providing an improved delivery of chemotherapeutics and
oxygen. Consequently, antiangiogenesis is expected to work
synergisticallywithradiotherapyandchemotherapy[23,24].
Given these ﬁndings, VEGF inhibitors are expected to be a
novel antiangiogenic therapy for malignant gliomas.
3. The Efﬁcacy andSafety of Bevacizumab for
RecurrentMalignantGliomas
3.1. Bevacizumab for Recurrent Glioblastoma. Bevacizumab
was developed as a humanized monoclonal antibody to bind
VEGF-A, preventing the interaction and activation of VEGF
receptor tyrosine kinases [25, 26]. This drug is approved by
the FDA and is in clinical use for the treatment of colorectal
cancer, nonsmall cell lung cancer, breast cancer, renal cell
carcinoma, and glioblastoma [27]. Table 1 shows several
clinical studies of bevacizumab for recurrent malignant
glioma patients.
The ﬁrst phase II trial for 35 recurrent glioblastoma
was performed to investigate the eﬃcacy of intravenous
administration of bevacizumab and irinotecan, a topoiso-
merase 1 inhibitor [11]. The 6-month PFS was 46%, and
median overall survival was 10.5 months, respectively. At
least a partial response was observed in 57% of patients. A
larger, randomized, noncomparative phase II study, called
the BRAIN study, was performed using bevacizumab with
or without irinotecan for 167 recurrent glioblastoma. In
this study, the response rates were 28.2% and 37.8%,
and 6-month PFS were 42.6% and 50.3% in bevacizumab
alone and bevacizumab plus irinotecan groups, respectively
[12]. Another phase II study of bevacizumab alone for 48
recurrent glioblastomas showed that response rate was 35%
and 6-month PFS was 29%, respectively [13]. These results
were more favorable than a previous database of 8 negative
trials having 6-month PFS of 15% for recurrent glioblas-
toma patients [7]. Furthermore, an additional advantage of
bevacizumab is its ability to decrease tumor edema and to
reduce steroid dose. Given the eﬃcacy of bevacizumab for
recurrent glioblastoma in the clinical setting, bevacizumab
monotherapy has since been approved by the FDA.
3.2. Toxicity Proﬁle of Bevacizumab. Since VEGF plays an
important role in vascular function and physiological angio-
genesis, its inhibition via bevacizumab has been reported
to cause serious adverse events [34]. The ﬁrst phase II
study of recurrent glioblastoma treated by bevacizumab and
irinotecan reported that ﬁve patients (14%) discontinued
treatment due to central nervous system (CNS) hemorrhage,
deep venous thrombosis, and pulmonary emboli [11]. No
fatal adverse events were reported in this study. BRAIN
study reported the detailed information on adverse events of
bevacizumab [12]. Grade ≥3 adverse events were observed
in 65.8% and 46.4% of bevacizumab plus irinotecan and
bevacizumab alone groups, respectively. The most com-
mon causes of grade ≥3 adverse events were convulsion,
hypertension, neutropenia, and fatigue. CNS hemorrhages
of any grades were observed in ﬁve patients (3.0%). There
were one fatal adverse event (1.3%) in bevacizumab plus
irinotecan group and two (2.3%) in bevacizumab alone
group, respectively. Selecting appropriate patients, early
assessment of toxicity, and adequate management should be
requiredtoreducetheseriousadverseeventsofbevacizumab.
Arterial and venous thromboses are generally reported
in treatment of antiangiogenesis therapy, although the
inherent risk of these thromboses is higher among malignant
glioma patients. A retrospective study of 9849 patients with
malignant gliomas showed that 2-year cumulative incidence
of symptomatic venous thromboembolism was 7.5% [35].
Further studies are necessary to evaluate the additional
risk of thrombosis in malignant glioma patients treated by
bevacizumab.
Recently, a meta-analysis of randomized control trials
in several tumor types showed that bevacizumab in com-
bination with chemotherapy increases fatal adverse events
when compared with chemotherapy alone [36]. The overall
incidence of fatal adverse events was 2.5% in bevacizumab
therapy with the common causes being hemorrhage, neu-
tropenia,andgastrointestinaltractperforation.Interestingly,
the type of chemotherapeutic agents was signiﬁcantly associ-
ated with relative risk of fatal adverse events. The addition
of bevacizumab was associated with increased fatal adverse
eventsinpatientsreceivingtaxanesorplatinumagents(3.3%
versus 1.0%) but not in those receiving other agents (0.8%
versus 0.9%). In clinical trials of malignant gliomas, the
addition of irinotecan or temozolomide to bevacizumab has
often been performed and may be associated with lower fatal
adverse events. However, this meta-analysis did not include
the trials of brain tumors, and further investigations are
required to evaluate the fatal adverse events of bevacizumab
and chemotherapy in malignant gliomas.
3.3. Bevacizumab for Recurrent Anaplastic Gliomas. Anaplas-
tic gliomas have a slightly better prognosis than glioblas-
toma [37], and the median survival time is 2 to 3 years.
However, there are no standard treatments for progression
or recurrence of anaplastic gliomas, and a novel treatmentJournal of Oncology 3
Table 1: Bevacizumab for recurrent or newly malignant gliomas.
Study Agents Patients RR MPFS 6-PFS MST Ref.
Phase II Bevacizumab + irinotecan 35 recurrent GBM 57% 6 months 46% 10.5 months [11]
Phase II Bevacizumab 85 recurrent GBM 28% 4.2 months 43% 9.2 months
Bevacizumab + irinotecan 82 recurrent GBM 38% 5.6 months 50% 8.7 months
[12]
Phase II Bevacizumab 48 recurrent GBM 35% 4 months 29% 7.7 months [13]
Phase II Bevacizumab + irinotecan 23 recurrent GBM 61% 5.0 months 30% 10 months
9 recurrent AG 67% 7.5 months 56% Not reached
[28]
Phase II Bevacizumab + irinotecan 33 recurrent AG 61% 7.5 months 55% 16.3 months [29]
Retrospective Bevacizumab + SRT 20 recurrent GBM 50% 7.3 months 65% 12.5 months [30]
5 recurrent AG 60% 7.5 months 60% 16.5 months
Retrospective SRS + bevacizumab — 5.2 months — 11.2 months
[31]
SRS + other drugs
49 recurrent GBM
— 2.1 months — 3.9 months
Phase II Bevacizumab + erlotinib 25 recurrent GBM 48% 4.5 months 28% 10.5 months
32 recurrent AG 31% 5.9 months 44% 17.8 months
[32]
Phase II Bevacizumab + RT/TMZ 70 newly diagnosed
GBM — 13.6 months 88% 19.6 months [14]
Phase II Bevacizumab + RT/TMZ 125 newly diagnosed
GBM — 13.8 months 87% — [15]
Phase II Adjuvant bevacizumab 125 newly diagnosed
+ irinotecan + TMZ GBM — 13.8 months — 21.3 months [33]
RR:responserate;MPFS:medianprogression-freesurvival;6-PFS:6-monthprogression-freesurvival;MST:medianoverallsurvivaltime;GBM:glioblastoma
multiforme; AG: anaplastic gliomas; SRT: stereotactic radiotherapy; SRS: stereotactic radiosurgery; RT: radiotherapy; TMZ: temozolomide.
strategy is needed. Recent studies have shed light on the
antiangiogenic therapy in recurrent anaplastic gliomas. A
phaseIIstudyofbevacizumabandirinotecan wasperformed
in 23 glioblastoma and 9 anaplastic gliomas [28]. The
response rates were 61% and 67%, and 6-month PFS were
30% and 56% in glioblastoma and anaplastic gliomas,
respectively. Another phase II trial was conducted for 33
anaplastic gliomas treated by bevacizumab and irinotecan
[29]. This study included 25 anaplastic astrocytomas and
8 anaplastic oligodendrogliomas. The 6-month PFS and
overall survivals were 55% and 79%, respectively. At least
a partial response was observed in 61% of patients, and
doseofdexamethasonewasdecreasedin67%.Theseﬁndings
indicate that bevacizumab and irinotecan can be an active
regimen for recurrent anaplastic gliomas.
3.4. Additional Treatment to Bevacizumab for Recurrent
Malignant Gliomas. The addition of targeting therapy or
radiotherapy to bevacizumab has been performed for recur-
rent malignant gliomas. Gutin et al. retrospectively analyzed
bevacizumab and stereotactic radiotherapy (30Gy in 5 frac-
tions) for 25 recurrent malignant gliomas [30]. There were
20 glioblastomas and 5 anaplastic gliomas in this study with
all patients receiving prior radiotherapy. Response rate was
50%, and 6-month PFS was 65% in glioblastoma patients.
Three patients (12%) discontinued treatment due to tumor
hemorrhage, wound dehiscence, and bowel perforation,
although no radiation necrosis was detected. The authors
concluded that treatment was well tolerated and beneﬁcial
for recurrent malignant gliomas. Cuneo et al. retrospectively
evaluated the eﬃcacy and safety of stereotactic radiosurgery
and adjuvant bevacizumab for recurrent malignant gliomas
[31].MedianPFSwas5.2months,and1-yearoverallsurvival
was 50% in glioblastoma patients treated by radiosurgery
and adjuvant bevacizumab. These results were signiﬁcantly
better than radiosurgery and other drugs. The authors con-
cluded that salvage radiosurgery and bevacizumab improve
outcomes in recurrent malignant gliomas.
AphaseIIstudyofbevacizumabpluserlotinib,anepider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor,
wasperformedforpatientswithrecurrentmalignantgliomas
[32]. This study included 25 glioblastomas and 32 anaplastic
gliomas. The response rate and 6-month PFS were 48%
and 28% for glioblastoma and 31% and 44% for anaplastic
gliomas, respectively. Grade 1 or 2 rash, mucositis, diarrhea,
and fatigue were the most common adverse events. The
authors concluded that treatment was tolerated, but the
additional beneﬁts of erlotinib were unclear when compared
with historical bevacizumab-containing regimens. These
studies indicate that additional therapy to bevacizumab can
be promising strategy, although it is still unclear which
agent has the eﬃcacy in combination with bevacizumab for
malignant gliomas. Further studies are required to establish
the additional agents to bevacizumab.
4.Resistance toBevacizumab
In the maintenance of bevacizumab, patients with malig-
nant gliomas inevitably experience tumor recurrence. Fur-
thermore, recurrent tumors after bevacizumab failure are4 Journal of Oncology
reported to be more aggressive with rebound edema [38].
Although additional agents to bevacizumab have been
attempted for patients after bevacizumab failure, disease
prognosis was extremely poor with median PFS of 37.5 days
and 6-month PFS of 2%, respectively [39]. The authors
concluded that alternative strategies should be considered
for these patients. De Groot et al. showed that bevacizumab
induced a particularly invasive tumor phenotype expressing
insulin-like growth factor binding protein-2 and matrix
metalloprotease-2 in glioblastoma [40].
Preclinical studies indicated that alternative pro-angi-
ogenic signaling pathways are upregulated in resistance to
antiangiogenictherapies[41].Theseotherangiogenicfactors
such as ﬁbroblast growth factors and platelet-derived growth
factors (PDGF) can compensate for the loss of VEGF activ-
ity under bevacizumab treatment [42]. Additional agents
inhibiting other antiangiogenic pathways may suppress these
resistances, and furtherclinical and animal studies are clearly
required to overcome the resistance of bevacizumab.
5.ImagingofResponse to
Antiangiogenic Therapy
Most studies deﬁned partial and complete responses as radi-
ological objective response according to McDonald criteria
that are based on contrast-enhanced CT or MRI [43]. How-
ever, an accurate assessment of tumor response by conven-
tional modality is limited, since bevacizumab directly alters
tumorbloodvessels[44].Asaresultofthis,responserateand
6-month PFS are debatable as a measure of antitumor activ-
ity [44]. Norden et al. reported that bevacizumab suppressed
enhancing tumor recurrence, but not nonenhancing and
inﬁltrative tumor growth, indicating that bevacizumab may
change the recurrence patterns of malignant gliomas [45].
Iwamoto et al. reported that contrast-enhanced MRI did not
adequately evaluate disease status, whereas nonenhancing
tumor recurrence was signiﬁcantly associated with overall
survival in recurrent glioblastoma treated by bevacizumab
[46]. Given these ﬁndings, The Response Assessment in
Neuro-Oncology Working Group was established to develop
the new response criteria for clinical trials of brain tumors
[47]. They proposed to incorporate T2 and ﬂuid-attenuated
inversion recovery (FLAIR) changes on MRI to assess the
inﬁltrative pattern progression of malignant gliomas.
Other studies have looked into establishing a reliable
radiological modality in antiangiogenesis therapy. Positron
emission tomography (PET) using [18F] ﬂuorothymidine
(FLT)oﬀersnoninvasiveassessmentofcellproliferation[48].
The response measured by FLT-PET signiﬁcantly predicted
t h eo v e r a l ls u r v i v a li nr e c u r r e n tg l i o b l a s t o m at r e a t e db y
bevacizumab (P = 0.061) [49]. Recently, Ellingson et al.
reported that relative nonenhancing tumor ratio, the ratio
of FLAIR to contrast-enhancing volume, was predictive for
overall survival and PFS in the treatment of bevacizumab for
recurrent glioblastoma [50]. Further studies are warranted
to establish the imaging modality to evaluate the response to
antiangiogenic therapy and to predict the prognosis.
6.Biological MarkersPredictingResponse
A variety of biomarkers predicting the eﬃcacy of beva-
cizumabhavebeenreportedinseveraltumortypesincluding
malignant gliomas [51]. These predictive biomarkers are
expected to lead to a personalized therapy that selects
patientswhocanbeneﬁtfrombevacizumab.Sathornsumetee
et al. examined several biological markers in recurrent
malignant gliomas treated by bevacizumab and irinotecan
[52]. High VEGF expression was signiﬁcantly associated
with higher radiographic response (P = 0.024), and high
carbonic anhydrase 9 expression predicted poor overall
survival (P = 0.016). Higher hypoxia-inducible factor-2
alpha and VEGF receptor-2 expressions were also reported
to be associated with poor survival in recurrent malignant
gliomas treated by bevacizumab and erlotinib [32].
Recently, circulating VEGF concentrations are reported
to predict the prognosis in solid tumors treated by beva-
cizumab [51, 53]. The measurement of circulating proteins
is an attractive strategy since blood is easily accessible and
the assay is inexpensive. Circulating VEGF concentrations
are expected to reﬂect VEGF-dependent angiogenesis and
to predict the beneﬁt from bevacizumab [51]. Gururangan
et al. examined the VEGFR-2 phosphorylation in peripheral
blood mononuclear cells in recurrent malignant gliomas
and diﬀuse brainstem glioma treated by bevacizumab
[54]. They showed that circulating VEGFR-2 was inhibited
by bevacizumab, but they did not show information on
whether it is a prognostic biomarker. These clinical trials
have provided some potential predictive markers (e.g. tumor
VEGF expression or circulating markers), which require a
phase III study for proper evaluation [55].
7. Addition of Bevacizumab to
Temozolomide and Radiotherapy for
Newly DiagnosedGlioblastoma
Several clinical studies have been performed to evaluate
the safety and eﬃcacy of the addition of bevacizumab for
newly diagnosed glioblastoma (Table 1). Lai et al. reported
a phase II study of the addition of bevacizumab to the
standard treatment of temozolomide and radiotherapy for
70 newly diagnosed glioblastomas [14]. Bevacizumab was
intravenously administered every 2 weeks from the ﬁrst day
of treatment. The median overall survival and PFS were
19.6 and 13.6 months, respectively. The authors concluded
that the addition of bevacizumab improved PFS but not
overall survival when compared with a control group
treated with ﬁrst-line temozolomide and radiotherapy who
had mostly received bevacizumab at recurrence. Another
phase II study also reported preliminary results on the
addition of bevacizumab to the standard temozolomide and
radiotherapy regimen in 125 newly diagnosed glioblastomas
[15]. In this study, toxicity was minimal, and most patients
(90%) continued treatment, with median PFS of 13.8
months. Recently, Desjardins et al. reported a phase II study
of bevacizumab in combination with temozolomide plus
radiotherapy followed by bevacizumab, temozolomide, and
irinotecan for 125 newly diagnosed glioblastomas at theJournal of Oncology 5
Society for Neuro-Oncology (SNO) annual meeting in 2010
[33]. This study had median overall survival of 21.3 months
and PFS of 13.8 months, respectively. These studies showed
encouraging results; however, it is still unclear whether the
addition of bevacizumab to standard temozolomide and
radiotherapy can improve the overall survival.
Currently, two randomized phase III trials, ROTG 0825
and AVAGLIO, are ongoing for newly diagnosed glioblas-
toma treated by temozolomide and radiotherapy with or
without bevacizumab [56, 57]. These studies will show the
role of bevacizumab in frontline treatment in glioblastoma
patients.
8. The Effect of Bevacizumab on
Radiation Adverse Events
Bevacizumab has been reported to aﬀect the speciﬁc adverse
events of radiotherapy [58, 59]. Sherman et al. reported
that six glioblastoma patients developed severe radiation
optic neuropathy following bevacizumab [58]. All of them
received 60Gy in 30 fractions in the initial treatment.
Patients received a median of 7.5 doses of bevacizumab
followed by onset of visual symptoms. Although the detailed
mechanism remains unclear, the authors indicated that
bevacizumab decreases optic nerve tolerance to radiation.
Anothercaseseriesstudyreportedthatbevacizumabinduced
optic neuropathy and Brown-Sequard syndrome after irra-
diation [59]. The authors hypothesized that bevacizumab
following radiotherapy inhibits VEGF-dependent repair of
normal neural tissue.
In contrast, bevacizumab has been reported to be
eﬀective for the management of radiation necrosis and
retinopathy [60, 61]. Radiation necrosis is a serious com-
plication of radiotherapy and includes extended edema.
Pathological ﬁndings show that endothelial cell dysfunction
causes tissue hypoxia and necrosis with the local cytokine
release, including VEGF [62, 63]. Corticosteroids, surgery,
anticoagulation, and hyperbaric oxygen have been per-
formed, although there is no evidence to support routine use
in clinical practice [64]. Retrospective studies have shown
that bevacizumab decreased the edema and improved the
clinical outcome in patients with radiation necrosis [60, 65–
67]. Interestingly, a small randomized trial was recently
performed to demonstrate this eﬀect [68]. Patients having
radiation necrosis with progressive neurologic symptoms
were assigned to bevacizumab (n = 14) and placebo groups
(n = 7). Bevacizumab was intravenously administered
every 3 weeks for 12 weeks. Radiological response and
improvement of neurological symptoms were observed in
thebevacizumabtreatedgroupbutnotinplacebogroup.The
authors concluded that the class I evidence of bevacizumab
eﬃcacy for radiation necrosis was shown in this study.
Radiation retinopathy is a chronic and progressive con-
dition that results from radiation exposure. Retinal vascular
endothelial cell damage causes microaneurysms, telang-
iectasias, neovascularization, vitreous hemorrhage, macu-
lar edema, and tractional retinal detachment. Radiation
retinopathy has been treated by laser photocoagulation, cor-
ticosteroids, and anticoagulation, although the management
is still challenging [61]. Bevacizumab has been expected to
be a therapeutic modality for radiation retinopathy. Finger
reportedthatintravitrealinjectionofbevacizumabwaseﬀec-
tive for retinal hemorrhage, exudation, and edema, which
improvedvisualacuityofpatients [69].Therewereno ocular
and systemic side eﬀects by bevacizumab. Furthermore, the
authors recently showed that intravitreal bevacizumab was
eﬀective for radiation optic neuropathy [70].
Although these results indicate that some radiation
vasculopathies are potentially treatable by bevacizumab,
exacerbation of radiation necrosis by this drug was also
reported [71]. It is still unclear how bevacizumab aﬀects the
radiation adverse events. Meticulous followup is required
when bevacizumab is administered after radiotherapy. Ani-
mal models of radiation necrosis are needed to investigate
the mechanism of bevacizumab.
9. Other AntiangiogenicDrugs for
MalignantGliomas
VEGF has been shown to be the main player in tumor angio-
genesis, and its inhibitor, bevacizumab, has been thoroughly
investigated in clinical and animal studies. Other drugs such
as pan VEGF receptor tyrosine kinase inhibitors have also
been reported to inhibit VEGF pathways. Several biological
pathways including integrin, ﬁbroblast growth factor, and
PDGF also are associated with the angiogenesis. Currently,
several types of antiangiogenic drugs have been investigated
and used in clinical trials for recurrent as well as newly
diagnosed glioblastoma [72]. In this section, we review these
drugs and the results of clinical trials (Table 2).
9.1. Cilengitide. Cilengitide competitively binds αvβ3a n d
αvβ5 integrin receptors that are expressed on tumor cells
and activated endothelial cells during angiogenesis. Cilen-
gitide can directly inhibit the growth of integrin-expressing
tumor cells and indirectly act as an antiangiogenesis agent
[87, 88]. Glioblastoma cells express integrin receptors, and
cilengitide has shown an antitumor eﬀect in glioblastoma
xenografts in vivo [89, 90]. A randomized phase II study
of 81 recurrent glioblastoma was performed to determine
the eﬃcacy and safety of cilengitide [73]. The patients
were randomly assigned to receive either 500 or 2000mg
of cilengitide twice weekly. Patients treated with 2000mg
showed a trend toward better results with 6-month PFS
of 15%. The treatment was well tolerated, and signiﬁcant
hematologic toxicity was uncommon. A phase I/IIa study of
cilengitide combined with temozolomide and radiotherapy
for 52 newly diagnosed glioblastoma patients was conducted
[74]. This combination therapy was well tolerated without
additional toxicity, and median overall survival was 16.1
months. The authors concluded that this regimen showed
promising activity against newly diagnosed glioblastoma
when compared with historical controls. Based on these
results, two randomized trials, CENTRIC and CORE, are
currently ongoing to determine the eﬃcacy of cilengitide for
newly diagnosed glioblastoma with or without a methylated6 Journal of Oncology
Table 2: Other antiangiogenesis drugs for recurrent or newly diagnosed malignant gliomas.
Target Study Agent Patients RR MPFS 6-PFS MST Ref.
Integrin Cilengitide (500mg/day) 41 recurrent GBM 5% 7.9 months 10% 6.5 months II
(2000mg/day) 40 recurrent GBM 13% 8.1 months 15% 9.9 months [73]
Integrin I/IIa Cilengitide + RT/TMZ 52 Newly diagnosed
GBM — 8.0 months 69% 16.1 months [74]
bFGF II Thalidomide 39 recurrent MG 6% 2.5 months — 7.0 months [75]
bFGF II Thalidomide + carmustine 40 recurrent MG 24% 3.3 months 28% — [76]
bFGF II Thalidomide + irinotecan 32 recurrent GBM 6% 3.3 months 25% 9.0 months [77]
bFGF I Lenalidomide 24 recurrent GBM 0% 1.8 months 13% 6.0 months [78]
VEGFR II Cediranib (45mg/day) 31 recurrent GBM 27% 3.9 months 26% 7.6 months [79]
Cediranib (30mg/day) 325 recurrent GBM — — 16% —
VEGFR III Cediranib (20mg/day) + lomustine — — 35% — [33]
Lomustine + placebo — — 26% —
VEGFR II Adjuvant sorafenib + TMZ 47 newly diagnosed
GBM 13% 6.0 months 50% 12 months [80]
VEGFR II Sunitinib 21 recurrent MG 0% 1.6 months — 3.8 months [81]
VEGFR I Vatalanib + RT/TMZ 19 newly diagnosed
GBM 13% 7.2 months — 16.2 months [82]
VEGFR II Pazopanib 35 recurrent GBM 6% 3.0 months 3% 8.8 months [83]
PDGFR II Imatinib 31 recurrent GBM 6% 1.7 months 16% 5.2 months [84]
PDGFR
Imatinib 120 recurrent GBM — 1.5 months 7% 5.3 months
III Imatinib + hydroxyurea 120 recurrent GBM — 1.5 months 5% 4.8 months [85]
PDGFR R Dasatinib 14 recurrent GBM 0% 0.9 months 0% 2.6 months [86]
RR:responserate;MPFS:medianprogression-freesurvival;6-PFS:6-monthprogression-freesurvival;MST:medianoverallsurvivaltime;GBM:glioblastoma
multiforme;RT:radiotherapy;TMZ:temozolomide;bFGF:basicﬁbroblastgrowthfactor;MG:malignantgliomas;VEGFR:vascularendothelialgrowthfactor
r e c e p t o r ;P D G F R :p l a t e l e t - d e r i v e dg r o w t hf a c t o rr e c e p t o r ;R :r e t r o s p e c t i v e .
O6-methylguanine-DNA methyltransferase (MGMT) pro-
moter [91, 92].
9.2. Thalidomide and Lenalidomide. Thalidomide was devel-
oped as a sedative drug in 1950s and was withdrawn due
to teratogenic eﬀects. However, thalidomide was recently
reported to have an antiangiogenic activity by inhibiting
basic ﬁbroblast growth factor (bFGF) [93], which can
be exploited as an antitumor drug. Several clinical trials
have been performed to assess the eﬃcacy and safety
of thalidomide for vascular tumors including malignant
gliomas. This drug has since been approved by the FDA
for the treatment of malignant myeloma [94]. Fine et
al. showed a phase II study of thalidomide alone for 39
patientswithrecurrentmalignantgliomas[75].Thalidomide
was well tolerated with modest sedation and constipation,
although median PFS and overall survival were 2.5 months
and 7.0 months, respectively. Another phase II study of
thalidomide combined with carmustine was performed for
40 recurrent malignant gliomas [76]. Although the addition
ofcarmustineseemedtoimprovetheprognosis,theresponse
rateandmedianPFSofcombinationgroupwere24%and3.3
months, respectively. Puduvalli et al. reported a phase II trial
of thalidomide and irinotecan for 32 recurrent glioblastomas
[77]. The combination therapy was well tolerated with mild
myelosuppression and sedation. At least a partial response
was detected in two patients (6%), and 6-month PFS was
25%, respectively. These results indicate that thalidomide
plus cytotoxic agents seem to have a mild antitumor activity
for recurrent malignant gliomas patients when compared
with thalidomide alone.
Lenalidomide, a potent structural and functional thali-
domide analog, has antiangiogenic, anti-inﬂammatory, and
immunomodulatory activities in preclinical studies [95, 96].
This drug is approved by the FDA for myelodysplastic syn-
dromewithchromosome5qdeletionandmultiplemyeloma.
Recently, lenalidomide has been performed for recurrent
brain tumors in clinical trials [78, 97]. Fine et al. reported
that lenalidomide was well tolerated; however, no objective
responses were seen in a phase I study [78]. Median 6-month
PFS was 12.5% in recurrent glioblastoma patients. Warren et
al. conducted a phase I study of lenalidomide for pediatric
patients with recurrent or progressive brain tumors [97].
This treatment was well tolerated with the primary toxicity
being myelosuppression. Partial responses were seen in two
patients (4%) with low-grade gliomas. Because these studies
were phase I trials, further investigations are required to
evaluate the antitumor activity for malignant gliomas.
9.3. VEGF Receptor Tyrosine Kinase Inhibitors (Cediranib,
Sorafenib, Sunitinib, Vatalanib, and Pazopanib). Currently,
VEGF receptor tyrosine kinase inhibitors are viewed asJournal of Oncology 7
promising antiangiogenic agents in the setting of malignant
gliomas. Cediranib was developed as an oral pan-VEGF
receptor tyrosine kinase inhibitor. Preclinical studies showed
that cediranib normalized tumor vasculature and decreased
the edema in glioblastoma, improving the prognosis without
inhibition of tumor growth [98, 99]. Batchelor et al.
conducted a phase II study of cediranib for 31 recurrent
glioblastoma patients [79]. Patients were administered a
45mg/day dose of cediranib. Partial response according to
the MacDonald criteria was observed in 26.6% of patients,
and 6-month PFS was 25.8%. Corticosteroids were reduced
or discontinued in 27% of patients. Toxicities were man-
ageable, and common Grade 3 to 4 toxicities were fatigue,
hypertension, and diarrhea. Furthermore, they showed the
changes of growth factors in plasma after cediranib (e.g.,
bFGF, VEGF receptor 1, and matrix metalloproteinase-2),
which were associated with treatment response or survival in
this therapy. Based on these promising results, the authors
conducted a phase III study of cediranib for 325 patients
withrecurrentglioblastoma,andthepreliminaryresultswere
reported at the 2010 SNO annual meeting [33]. Patients
were assigned on a 2:2:1 ratio to cediranib monother-
apy 30mg/day, combination of cediranib 20mg/day plus
lomustine,andlomustinemonotherapyplusplacebogroups.
The 6-month PFS was 16% in cediranib monotherapy,
34.5% in the combination, and 25.8% in lomustine plus
placebo groups, respectively, although the results were not
signiﬁcantly diﬀerent between these groups. The eﬃcacy of
cediranibmonotherapyseemstobelessthantheinitialphase
II study, and the possible reason for this discrepancy is that
diﬀerent doses of cediranib were used between two studies.
Sorafenib and sunitinib are inhibitors of multiple recep-
tor tyrosine kinases including VEGF receptor. Sorafenib was
approved by the FDA for the treatment of advanced renal cell
carcinoma and hepatocellular carcinoma [100]. Hainsworth
et al. conducted a phase II trial of concurrent radiotherapy
and temozolomide followed by adjuvant sorafenib and
temozolomide for 47 newly diagnosed glioblastomas [80].
This regimen was well tolerated without signiﬁcant grade
3 or 4 toxicities, although median overall survival and PFS
were 12 months and 6 months, respectively. The authors
concluded that the addition of sorafenib did not appear
to improve the prognosis of these patients. Sunitinib was
reported in a phase II study of 21 recurrent malignant
gliomas [81]. No objective responses were detected, and
median overall survival and PFS were 3.8 and 1.6 months,
respectively. This study showed that single-agent sunitinib
had insuﬃcient activity for recurrent malignant gliomas.
Vatalanib is a small molecule inhibitor of VEGF receptor,
PDGF receptor, and c-kit. In a phase I trial, vatalanib
was added to the standard regimen of temozolomide and
radiotherapy for 19 newly diagnosed glioblastomas [82].
Response rate was13%, and median overall survivalwas 16.2
months, respectively. Pazopanib is a multitargeted tyrosine
kinase inhibitor, including VEGF receptor-1, -2, and -3. A
phase II trial of pazopanib was performed for recurrent
glioblastoma [83]. However, this drug did not have enough
antitumor activity with response rate of 5.7% and median
PFS of 3.0 months.
Despite several trials of VEGF receptor tyrosine kinase
inhibitors, the eﬃcacy has not been established. In a
retrospectivestudyofglioblastomapatientswhofailedVEGF
receptor tyrosine kinase inhibitors, bevacizumab salvage
therapy still provided beneﬁts with response rate of 21%
and 6-month PFS of 12.5%, respectively [101]. Although
there are no comparative studies, VEGF receptor inhibition
therapy may be less eﬀective for malignant gliomas when
compared with bevacizumab [102].
9.4. PDGF Receptor Tyrosine Kinase Inhibitor (Imatinib, Da-
satinib, and Tandutinib). The PDGF pathway also plays
a role in angiogenesis [103]. PDGF receptor inhibitors
(e.g., imatinib, dasatinib, and tandutinib) have been per-
formed in clinical trials of malignant gliomas. Imatinib is
a multitargeted tyrosine kinase inhibitor and blocks PDGF
receptor α,P D G Fr e c e p t o rβ, and c-KIT receptor. Preclinical
study has demonstrated the antitumor eﬀect of imatinib on
glioblastoma cell lines [104]. A phase II study of imatinib
was performed for 112 recurrent gliomas [84]. The 6-month
PFS was 16% in glioblastoma, 4.0% in pure/mixed anaplastic
oligodendrogliomas, and 9% in low-grade or anaplastic
astrocytoma. In 31 glioblastoma patients, response rate was
6%, and median survival was 5.2 months, respectively. This
study indicated that single agent imatinib was well tolerated
but had limited antitumor activity. A randomized phase III
study was conducted for 240 recurrent glioblastoma patients
treated by hydroxyurea with or without imatinib [85]. The
results from the two arms were very similar, and 6-month
PFS was 5% in the combination arm and 7% in the imatinib
alone arm, respectively. The authors concluded that there
werenoclinicalbeneﬁtsfromtheadditionofimatinib.Taken
together, these results suggest that imatinib is discouraged in
recurrent glioblastoma patients.
Dasatinib and tandutinib are oral molecule inhibitors
of several targets, including PDGF and c-kit. Dasatinib was
approved by FDA for the treatment of chronic myelogenous
leukemia [105]. A retrospective study reported the eﬃcacy
of dasatinib for 14 recurrent glioblastomas who failed
bevacizumab therapy [86]. However, objective response rate
was 0%, and 6-month PFS was 0%, respectively. Currently,
a phase II trial of dasatinib (RTOG 0627) is ongoing to
evaluate the eﬃcacy and safety for recurrent glioblastoma
or gliosarcoma [106]. Combined treatments with tandutinib
and bevacizumab are being performed in a phase II study
for recurrent malignant gliomas [107]. Preliminary results
cautioned that neuromuscular junction dysfunction was
observed in this regimen.
Although PDGF receptor inhibitors are eﬀective in
preclinical studies, it is still unclear whether these drugs
have an antitumor eﬀect in malignant glioma patients. One
possible reason for the limited antitumor eﬀect is that PDGF
receptor inhibitor such as imatinib cannot cross the blood-
brain barrier via the P-glycoprotein eﬄux pump [108].
10.SummaryandPerspectives
Despite advances in treatment therapeutics, patients with
malignant gliomas still have poor prognosis. A better8 Journal of Oncology
understanding of tumor angiogenesis has allowed us to
target VEGF in antiangiogenic therapy. Bevacizumab is
considered as a well-established antiangiogenic therapy in
s e v e r a ls o l i dt u m o r s .Ap h a s eI It r i a l so fr e c u r r e n tg l i o b l a s -
toma showed favorable response rates (28% to 57%) and
6-month PFS (29% to 50.3%) [11–13]. Based on these
promisingresults,bevacizumabwasapprovedbytheFDAfor
the recurrent glioblastoma. Regarding recurrent anaplastic
gliomas, bevacizumab has been reported to be eﬀective
as well [28, 29]. Additional therapies (e.g., chemotherapy,
targeting therapy, and radiotherapy) to bevacizumab have
been reported for recurrent malignant gliomas, and these
results were encouraging. However, the timing, dosing, and
the ideal treatment partners of bevacizumab have remained
controversial. Further investigations are warranted to estab-
lish an antiangiogenic treatment for recurrent malignant
gliomas.
Bevacizumab is expected to be on the frontline treatment
of patients with glioblastoma. Phase II trials have reported
the addition of bevacizumab to standard temozolomide
and radiotherapy regimen for newly diagnosed glioblastoma
[14, 15]. However, the authors concluded that this regimen
improved PFS but not overall survival when compared
with control group [14]. Currently two randomized phase
III trials, RTOG 0825 and AVAGLIO, are ongoing to
demonstrate the eﬃcacy and safety of combined therapy
of bevacizumab, temozolomide, and radiotherapy for newly
diagnosed glioblastoma [56, 57]. These studies will show
the role of bevacizumab in the ﬁrst-line treatment of newly
diagnosed glioblastoma.
Many other antiangiogenic therapies (e.g., cilengitide
and cediranib) have also been performed in clinical trials.
These studies showed encouraging results and are expected
to improve the prognosis of malignant gliomas. However,
s o m ep h a s eI It r i a l sh a v es e v e r a ll i m i t a t i o n ss u c ha ss m a l l
sample size, possible enrollment bias, patient selection, and
reliance on historical control data. These limitations are
associatedwithahighfalse-positiverate,andtheresultsfrom
phase II studies are often not validated in phase III studies
[109].PhaseIIstudiesmustbeappropriatelyplannedtohave
the greatest potential for informing the design of phase III
trials [109].
Antiangiogenic therapies provide favorable results and
seem to be attractive strategy in malignant gliomas. How-
ever, several problems such as including severe toxicities,
resistance, evaluation of response, and lack of predictive
biomarkers still remain. The unique severe adverse eﬀects
related to bevacizumab have been reported, such as CNS
hemorrhage, deep venous thrombosis, and pulmonary
emboli [11–13]. BRAIN study reported that Grade ≥3
adverse events were observed 65.8% and 46.4% in beva-
cizumab plus irinotecan and bevacizumab alone groups,
respectively [13]. To reduce the serious adverse events
associated with bevacizumab, selecting appropriate patients,
early assessment of toxicity, and adequate management
should be required.
Malignant glioma patients maintained on bevacizumab
inevitably experience the treatment failure. Recurrent
tumors following bevacizumab failure appear to be more
aggressive with rebound edema [38]. Preclinical study
showed that other angiogenic factors, such as ﬁbroblast
growth factors and PDGF, can compensate for the loss of
VEGF activity under bevacizumab treatment [42]. A novel
therapeutic strategy is required to overcome the resistance to
bevacizumab of malignant gliomas.
An accurate assessment of tumor response by conven-
tional modality is limited in antiangiogenic therapy due
to alterations in tumor blood vessels [44]. The Response
Assessment in Neuro-Oncology Working Group proposed
that T2 and FLAIR changes on MRI should include the
responsecriteria[47].FDG-FLTisalsoexpectedtoaccurately
evaluate the treatment response in bevacizumab due to its
ability to detect cell proliferation [48].
Tumor VEGF expressions or circulating markers poten-
tially predict the prognosis in malignant glioma treated
by bevacizumab, although the rational biomarker has not
been established. Novel biological markers are required to
investigate, providing a personalized treatment that selects
the patients who can beneﬁt from bevacizumab.
Although several limitations on antiangiogenic therapy
have been reported, this treatment is expected to improve
the prognosis of malignant gliomas. Further investigation is
warranted to establish the safe and eﬀective antiangiogenic
therapy for malignant gliomas.
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